Biosimilars in Europe and The USA: Decode Market and Regulatory Scenarios

Biosimilars, which are viewed as supplements for their equivalent biologicals in terms of safety, quality and efficacy (if & when proved), are opined as value gainers in the days to come. An external survey predicts an exceptional surge in demand for these products whose value is expected to rise significantly by 2020. With many high-value petitions of biological products nearing their expiry, biosimilars can prove productive for manufacturers in the current scenario.

To understand the global outlook of biosimilars in terms of market and Regulatory perspectives, let us look at the market and Regulatory scenarios of biosimilars in two of the world’s biggest markets, the United States of America (USA) and Europe.

Know more at Freyr Page – Biosimilars in Europe and The USA: Decode Market and Regulatory Scenarios